Farther Finance Advisors’s Vera Therapeutics VERA Stock Holding History

Farther Finance Advisors’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$775	Buy	24 +9	+60%	+$315	﹤0.01%	5653
2026 Q2	$644	Sell	15 -7	-32%	-$261	﹤0.01%	5487
2026 Q1	$891	Sell	22 -6	-21%	-$259	﹤0.01%	5140
2025 Q4	$1.42K	Buy	28 +18	+180%	+$639	﹤0.01%	4810
2025 Q3	$291	Buy	+10	New	+$231	﹤0.01%	4649
2025 Q2	–	Sell	-26	Closed	-$573	–	4663
2025 Q1	$573	Buy	+26	New	+$835	﹤0.01%	3752

Other funds holding VERA

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $589M AUM 19.71% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors's VERA Position: Q3 2026 in Review

Farther Finance Advisors increased its Vera Therapeutics (VERA) stake by 60% in Q3 2026, buying an estimated $315 and bringing the position to 24 shares worth $775. The position accounts for ﹤0.01% of the portfolio, ranked #5653.

Farther Finance Advisors first reported a position in VERA in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.42K in Q4 2025. 6 funds tracked by Wall St. Rank hold VERA as of Q3 2026.

Farther Finance Advisors held 24 shares of Vera Therapeutics worth $775 as of Q3 2026.
Farther Finance Advisors bought 9 Vera Therapeutics shares in Q3 2026, an estimated $315.
Vera Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5653 holding.
Farther Finance Advisors first reported a position in Vera Therapeutics in Q1 2025 and has held it in 6 quarters since.
Farther Finance Advisors's Vera Therapeutics position peaked at $1.42K in Q4 2025.
6 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.